Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Homeland Security: Stryker, BD Devices Pose Hacking Risk

Executive Summary

The US Department of Homeland Security National Cybersecurity and Communications Integration Center is warning of potential cybersecurity vulnerabilities in Stryker hospital beds and BD diagnostics equipment.

You may also be interested in...



FDA Cybersecurity Forum: Manufacturers Explain Coordinated Vulnerability Disclosures

Device firms well-versed in carrying out coordinated vulnerability disclosures said it is important to secure company executive buy-in and to use the principles laid out in an evolving US FDA guidance on cybersecurity for assistance at a recent FDA cybersecurity meeting.

FDA Cybersecurity Forum: Trustworthiness, Threat Modeling Central Issues

US FDA hosted a range of device- and IT-industry stakeholders for a two-day event on medical device cybersecurity in pre-market submissions. The first day emphasized securing legacy software, authentication and encryption techniques, and risk assessment models, among other issues

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel